Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities

@article{MartnezBosch2019GalectinsIP,
  title={Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities},
  author={Neus Mart{\'i}nez-Bosch and A. Rodriguez-Vida and N. Juanpere and J. Lloreta and A. Rovira and J. Albanell and J. Bellmunt and P. Navarro},
  journal={Nature Reviews Urology},
  year={2019},
  volume={16},
  pages={433-445}
}
Advanced prostate and bladder cancer are two outstanding unmet medical needs for urological oncologists. The high prevalence of these tumours, lack of effective biomarkers and limited effective treatment options highlight the importance of basic research in these diseases. Galectins are a family of β-galactoside-binding proteins that are frequently altered (upregulated or downregulated) in a wide range of tumours and have roles in different stages of tumour development and progression… Expand
The Galectin Family as Molecular Targets: Hopes for Defeating Pancreatic Cancer
TLDR
The possible translation of recent results about galectin expression and functions in pancreatic cancer into clinical interventions (i.e., diagnosis, prediction of prognosis and/or therapy) for this fatal disease is discussed. Expand
Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis
TLDR
Findings identify Gal-3 as a key molecule and a potential therapeutic target already in the early phases of prostate cancer progression and metastasis. Expand
Comparative Immunohistochemical Study of Galectins 1, 3 and 9 in Ovarian Epithelial Neoplasms
TLDR
The significant increase in expression of galectin-1 and -3 in the epithelium of non- benign ovarian neoplasms suggests the participation of these galectins in ovarian carcinogenesis. Expand
Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach
Emerging research demonstrates that co-inhibitory immune checkpoints (ICs) remain the most promising immunotherapy targets in various malignancies. Nonetheless, ICIs have offered insignificantExpand
Post-Translational Modifications That Drive Prostate Cancer Progression
TLDR
A comprehensive list of proteome-wide and single protein post-translational modifications and their involvement in phenotypic outcomes is presented and current strategies that exploit the potential of post- Translated modifications in prostate cancer therapy are presented. Expand
Anticancer innovative therapy congress: Highlights from the 10th anniversary edition.
TLDR
Overall, this conference provided scientists and clinicians with a broad overview of future challenges and hopes to improve cancer treatment reasonably in the medium-short term. Expand
Functionalized nano-targeted moieties in management of prostate cancer.
TLDR
This review describes nano-targeting moieties for management of prostate cancer and its cancer stem cells and indicates that current research results are promising and may yield development of next-generation nanoscale theragnostic targeted modalities for prostate cancer treatment. Expand
The Gene Master Regulators (GMR) Approach Provides Legitimate Targets for Personalized, Time-Sensitive Cancer Gene Therapy
TLDR
It is proved experimentally that each patient has his/her own GMR, that cancer nuclei and surrounding normal tissue are governed by different GMRs, and that manipulating the expression has larger consequences for genes with higher GCH, and the hypothesis that silencing the GMR may selectively kill the cancer cells from a tissue is launched. Expand
1 The Gene Master Regulators ( GMR ) Approach 2 Provides Legitimate Targets for Personalized , 3 Time-Sensitive Cancer Gene Therapy 4
The dynamic and never exactly repeatable tumor transcriptomic profile of people 10 affected by the same form of cancer requires a personalized and time-sensitive approach of the 11 gene therapy. TheExpand
PET/CT Imaging with an 18F-Labeled Galactodendritic Unit in a Galectin-1–Overexpressing Orthotopic Bladder Cancer Model
TLDR
The 18F-labeled galactodendritic unit 4 and similar analogs may be clinically relevant and exploitable for PET imaging of galectin-1–overexpressing bladder tumors. Expand
...
1
2
...

References

SHOWING 1-10 OF 251 REFERENCES
Glycans and galectins in prostate cancer biology, angiogenesis and metastasis.
TLDR
Current evidence on both the expression and role of glycans and galectins in prostate cancer is summarized, particularly turning the authors' attention to the angiogenic and metastatic processes. Expand
Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer
TLDR
It is shown for the first time that the natural and conserved expression of Gal-8 in tumour cells is responsible for the metastatic evolution of prostate cancer and highlights Galectin-8 as a potential target for anti-metastatic therapy against prostate cancer. Expand
The role of glycans in the development and progression of prostate cancer
TLDR
Emerging data on changes in glycosylation have the potential to improve risk stratification and therapeutic strategies in patients with prostate cancer. Expand
Endogenous Galectin-1 in T Lymphocytes Regulates Anti-prostate Cancer Immunity
TLDR
Prostate tumors require Gal-1 in lymphocytes to evade immune responses, and this report lays the foundation for an original immunotherapy strategy for prostate cancer. Expand
A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.
TLDR
A dynamically regulated "galectin-specific signature" that accompanies disease evolution in prostate cancer is identified and highlighted, highlighting a major role for Gal-1 as a tractable target for antiangiogenic therapy in advanced stages of the disease. Expand
Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
TLDR
Loss of galectin-3 appears to be involved in the carcinogenesis of TCC and to serve as a valuable biological variable to identify a subgroup of Ta bladder cancer patients at high risk for the development of recurrent disease. Expand
Galectins in cancer: carcinogenesis, diagnosis and therapy.
TLDR
The results of a number of studies published over the past decade are condensed to shed some light on the unique role played by the galectin family of proteins in neoplasia, and how this knowledge may alter the approach to cancer diagnosis and therapy in the future. Expand
Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–stroma crosstalk
TLDR
Gal1 hierarchically regulates different events implicated in PDA biology including tumor cell proliferation, invasion, angiogenesis, inflammation, and metastasis, highlighting the broad therapeutic potential of Gal1-specific inhibitors, either alone or in combination with other therapeutic modalities. Expand
Proteomic Identification of the Galectin-1-Involved Molecular Pathways in Urinary Bladder Urothelial Carcinoma
TLDR
Proteomics results were further translated to prognostic markers by analyses of biopsy samples and demonstrated that over-expressions of glutamine synthetase, alcohol dehydrogenase, fatty acid binding protein 4, and toll interacting protein in clinical specimens were all significantly associated with galectin-1 up-regulation. Expand
Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion
TLDR
Evidence is provided that Gal-1 is an important target for m CRPC therapy, and LLS30 is a promising small-molecule compound that can potentially overcome mCRPC. Expand
...
1
2
3
4
5
...